Could two years of hormone therapy be enough for some breast cancers?

NCT ID NCT05297617

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether postmenopausal women with a very low-risk type of breast cancer (HR+ HER2-) can safely take hormone therapy for only 2-3 years instead of the standard 5 years. The goal is to maintain protection against cancer spread while reducing side effects and improving quality of life. Participants receive one of three aromatase inhibitors daily.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an aromatase inhibitor (letrozole, anastrozole, or exemestane)
What this could lead to
If successful, this could show that a shorter course of hormone therapy is safe for women with very low-risk breast cancer, sparing them years of side effects.
What could go wrong
This is a single-arm Phase 2 trial without a comparison group, so results may not be definitive. Shorter therapy might still carry a small risk of distant recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Hospitalier Universitaire de Limoges

    RECRUITING

    Limoges, 87042, France

    Contact Email: •••••@•••••

    Contact

    Contact

  • Institute Gustave Roussy

    NOT_YET_RECRUITING

    Villejuif, 94805, France

    Contact Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.